首页
小分子和化合物库
按“信号通路”分类
免疫学/炎症
CD20
Obinutuzumab (anti-CD20), CD20（跨膜 4-结构域；A 亚家族；成员 1）抗体

Obinutuzumab (anti-CD20), CD20（跨膜 4-结构域；A 亚家族；成员 1）抗体

级别和纯度:

≥95%(SDS-PAGE&SEC-HPLC)
见COA

应用:

Animal Model
ELISA
Flow Cytometry
Functional Assay

宿主种属: 人(Human)
种属反应性: 人(Human), 食蟹猴(Cynomolgus monkey)
亚型: Human IgG1
偶联: Unconjugated

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
O412011-100μg	100μg	现货
O412011-1mg	1mg	现货
O412011-5mg	5mg	现货

查看相关系列

点击查看靶蛋白信息: MS4A1

Accession#:P11836 (47) CD20 (48) CD20 (membrane-spanning 4-domains，subfamily A，member 1) Antibody (3) Gene ID:931 (47) Immunology/Inflammation (1938) MS4A1 (48)

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	Obinutuzumab (anti-CD20), CD20（跨膜 4-结构域；A 亚家族；成员 1）抗体
别名	奥比妥珠单抗(抗 CD20)
英文别名	B-lymphocyte surface antigen B1 \| Bp35 \| Leukocyte surface antigen Leu-16 \| Membrane-spanning 4-domains subfamily A member 1
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	MS4A1
应用	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
种属反应性	人(Human),食蟹猴(Cynomolgus monkey)
偶联	Unconjugated
作用类型	结合剂
作用机制	CD20（跨膜 4-结构域；A 亚家族；成员 1）抗体

产品属性

抗体类型	Primary antibody
克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG1
轻链亚型	kappa
SDS-PAGE	27.6 kDa (Light Chain) & 52.4 kDa (Heavy Chain), under reducing conditions; 179.0 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
来源	CHO supernatant
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	949142-50-1
分子类型	抗体

关联靶点（人）

MS4A1 Tclin B淋巴细胞抗原CD20(B-lymphocyte antigen CD20) (0 活性数据)

点击查看靶蛋白信息： MS4A1

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

图片

Flow Cytometry: Obinutuzumab (anti-CD20) (O412011)

Obinutuzumab (anti-CD20) (O412011) - Flow Cytometry
Flow Cytometry analysis of Raji cells labelling CD20 (red) with Obinutuzumab (anti-CD20) (O412011). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

SEC: Obinutuzumab (anti-CD20) (O412011)

Obinutuzumab (anti-CD20) (O412011) - SEC
The purity of Obinutuzumab (anti-CD20) (O412011) is more than 95% verified by HPLC.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到4个结果

批号(Lot Number)	证书类型	货号
ZJ23F0900984	分析证书	O412011
ZJ23F0900977	分析证书	O412011
ZJ24F0911261	分析证书	O412011
ZJ24F0911260	分析证书	O412011

技术文档和文章

流式细胞术实验方案

Categories: 实验方案（Protocols）

探索主题:

抗体流式细胞术流式抗体活性染料间接抗体标记

可替换产品

引用文献

1. Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S et al.. (2013) Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.. Mol Cancer Ther, 12 (10): (2031-42). [PMID:23873847]
2. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P et al.. (2004) The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).. Genome Res, 14 (10B): (2121-7). [PMID:15489334]
3. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K et al.. (2004) Complete sequencing and characterization of 21,243 full-length human cDNAs.. Nat Genet, 36 (1): (40-5). [PMID:14702039]
4. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, Beaumont T, Tedder TF, van Noesel CJ, Eldering E et al.. (2010) CD20 deficiency in humans results in impaired T cell-independent antibody responses.. J Clin Invest, 120 (1): (214-22). [PMID:20038800]
5. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM. (2004) Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.. Clin Cancer Res, 10 (8): (2868-78). [PMID:15102696]
6. Le Garff-Tavernier M, Decocq J, de Romeuf C, Parizot C, Dutertre CA, Chapiro E, Davi F, Debré P, Prost JF, Teillaud JL et al.. (2011) Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.. Leukemia, 25 (1): (101-9). [PMID:20975664]
7. Li B, Xu L, Pi C, Yin Y, Xie K, Tao F, Li R, Gu H, Fang J. (2017) CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy.. Oncoimmunology, 7 (1): (e1380142). [PMID:29296544]
8. Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, Yan X, Clark R, Reyes A, Stefanich E et al.. (2015) Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.. Sci Transl Med, 7 (287): (287ra70). [PMID:25972002]
9. Todd D Taylor,Hideki Noguchi,Yasushi Totoki,Atsushi Toyoda,Yoko Kuroki,Ken Dewar,Christine Lloyd,Takehiko Itoh,Tadayuki Takeda,Dae-Won Kim,Xinwei She,Karen F Barlow,Toby Bloom,Elspeth Bruford,Jean L Chang,Christina A Cuomo,Evan Eichler,Michael G FitzGerald,David B Jaffe,Kurt LaButti,Robert Nicol,Hong-Seog Park,Christopher Seaman,Carrie Sougnez,Xiaoping Yang,Andrew R Zimmer,Michael C Zody,Bruce W Birren,Chad Nusbaum,Asao Fujiyama,Masahira Hattori,Jane Rogers,Eric S Lander,Yoshiyuki Sakaki. (2006-03-24) Human chromosome 11 DNA sequence and analysis including novel gene identification.. Nature, 440 ((7083)): (497-500). [PMID:16554811]
10. Tedder, T F TF, Streuli, M M, Schlossman, S F SF and Saito, H H.. (1988) Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2448768]
11. Einfeld, D A DA, Brown, J P JP, Valentine, M A MA, Clark, E A EA and Ledbetter, J A JA.. (1988) Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains.. The EMBO journal, [PMID:2456210]
12. Tedder, T F TF, Klejman, G G, Schlossman, S F SF and Saito, H H.. (1989) Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1).. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:2466899]
13. Stamenkovic, I I and Seed, B B.. (1988) Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein.. The Journal of experimental medicine, (1): [PMID:3260267]
14. Tedder, T F TF, Boyd, A W AW, Freedman, A S AS, Nadler, L M LM and Schlossman, S F SF.. (1985) The B cell surface molecule B1 is functionally linked with B cell activation and differentiation.. Journal of immunology (Baltimore, Md. : 1950), [PMID:3925015]
15. Bubien, J K JK, Zhou, L J LJ, Bell, P D PD, Frizzell, R A RA and Tedder, T F TF.. (1993) Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes.. The Journal of cell biology, [PMID:7684739]
16. and Goldenberg, D M DM.. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy.. Critical reviews in oncology/hematology, [PMID:11418316]
17. Chen, X X, Ji, Z L ZL and Chen, Y Z YZ.. (2002) TTD: Therapeutic Target Database.. Nucleic acids research, (1): [PMID:11752352]
18. and Dillman, R O RO.. Monoclonal antibody therapy for lymphoma: an update.. Cancer practice, [PMID:11879282]
19. (2003) Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, [PMID:12899647]
20. Li, Haidong H, Ayer, Linda M LM, Lytton, Jonathan J and Deans, Julie P JP.. (2003) Store-operated cation entry mediated by CD20 in membrane rafts.. The Journal of biological chemistry, (24): [PMID:12920111]
21. Du, Jiamu J and 8 more authors.. (2008) Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide.. Molecular immunology, [PMID:18346788]
22. Dörner, Thomas T and Burmester, Gerd R GR.. (2008) New approaches of B-cell-directed therapy: beyond rituximab.. Current opinion in rheumatology, [PMID:18388516]
23. Polyak, Maria J MJ, Li, Haidong H, Shariat, Neda N and Deans, Julie P JP.. (2008) CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins.. The Journal of biological chemistry, (4): [PMID:18474602]
24. Niederfellner, Gerhard G and 16 more authors.. (2011) Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies.. Blood, (14): [PMID:21444918]
25. Ivaldi, Corinne C and 6 more authors.. (2012) Proteomic analysis of S-acylated proteins in human B cells reveals palmitoylation of the immune regulators CD20 and CD23.. PloS one, [PMID:22615937]
26. Phuah, Jiayao J and 10 more authors.. (2016) Effects of B Cell Depletion on Early Mycobacterium tuberculosis Infection in Cynomolgus Macaques.. Infection and immunity, [PMID:26883591]
27. Hayashi, Kazumi and 6 more authors.. (2016) Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.. Cancer science, [PMID:26920337]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Obinutuzumab (anti-CD20), CD20（跨膜 4-结构域；A 亚家族；成员 1）抗体

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

质检证书（CoA,COO,BSE/TSE 和分析图谱)

技术文档和文章

相关产品

可替换产品

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器